US equities |
INTC $66.14 ▼-28.17% AMZN $241.09 ▼-1.11% MU $890.06 ▼-4.73% NVDA $206.36 ▼-3.42% GOOGL $282.24 ▼-0.56% SNDK $1,189.68 ▼-10.55% SPCX $138.22 ▼-3.94% AMD $513.66 ▼-9.31%
FinancialContent

ZyVersa Therapeutics, Inc. - Common Stock (NQ:ZVSA)

0.3113 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ZyVersa Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
“Trump Media (NASDAQ: DJT) Surges on Election Day as SmallCap Stocks CRDL, ALBT, ZVSA, PRSO Emerge”
Via AB Newswire
Topics Government
News headline image
Dow Jumps 400 Points; Yum! Brands Posts Downbeat Earnings ↗
 
Via Benzinga
Topics Stocks
News headline image
S&P 500 Gains 1%; Vimeo Shares Spike Higher ↗
 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Nasdaq Gains Over 100 Points; US Trade Deficit Widens In September ↗
 
Via Benzinga
News headline image
Peering Into ZyVersa Therapeutics's Recent Short Interest ↗
 
Via Benzinga
News headline image
ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes
From ZyVersa Therapeutics
Via GlobeNewswire
News headline image
Why Palantir Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs
From ZyVersa Therapeutics
Via GlobeNewswire
News headline image
ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases
From ZyVersa Therapeutics
Via GlobeNewswire
News headline image
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months
From ZyVersa Therapeutics
Via GlobeNewswire
News headline image
ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors
Lead indication for ZyVersa’s Inflammasome ASC Inhibitor IC 100 is obesity with metabolic complications. 
From ZyVersa Therapeutics
Via GlobeNewswire
News headline image
ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications
From ZyVersa Therapeutics
Via GlobeNewswire
News headline image
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
ZVSA Stock Earnings: ZyVersa Therapeutics Beats EPS for Q2 2024 ↗
ZVSA stock results show that ZyVersa Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update
From ZyVersa Therapeutics
Via GlobeNewswire
News headline image
ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation
From ZyVersa Therapeutics
Via GlobeNewswire
News headline image
ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults
From ZyVersa Therapeutics
Via GlobeNewswire
News headline image
ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100
From ZyVersa Therapeutics
Via GlobeNewswire
News headline image
ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model
From ZyVersa Therapeutics
Via GlobeNewswire
SmallCap Tech/Biotech Stocks July/Aug 2024: ZVSA, DYAI, ZVRA, PRSO, RLMD, VTAK, ENTO, INBS, KAVL
Via AB Newswire
News headline image
ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 3rd Annual Kidney Conference to be Held Virtually on July 15, 2024
From ZyVersa Therapeutics
Via GlobeNewswire
News headline image
ZVSA Stock Earnings: ZyVersa Therapeutics Misses EPS for Q1 2024 ↗
ZVSA stock results show that ZyVersa Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update
From ZyVersa Therapeutics
Via GlobeNewswire
News headline image
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention
From ZyVersa Therapeutics
Via GlobeNewswire
News headline image
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
 
Via Benzinga
News headline image
What's Going On With ZyVersa Stock? ↗
ZyVersa Therapeutics shares are trading higher Monday after the company announced the publication of a scientific paper in a peer-reviewed journal that reinforces the rationale for inhibiting ASC with... 
Via Benzinga
News headline image
ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease
From ZyVersa Therapeutics
Via GlobeNewswire
News headline image
ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes
From ZyVersa Therapeutics
Via GlobeNewswire
News headline image
Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >